Head-to-head · WeighScore
Kina vs Queen RX
The verdict
Kina takes it — 70.1/100 to 66.3/100.
Kina grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kina is a menopause-care telehealth platform where GLP-1 is the weight-loss treatment, offered alongside HRT, peptide, and compounded options for menopause symptoms.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Kina | Queen RX |
|---|---|---|
| WeighScore | 70.1/100 | 66.3/100 |
| Grade | C | C |
| Scorecard rank | #107 | #192 |
| Semaglutide | $179/mo (starting dose, plus a separate fee, compounded) | $100/mo (quarterly plan, compounded) |
| Tirzepatide | $179/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | 45 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #107 · C
Strengths
- Menopause-specialized care — GLP-1 weight treatment alongside HRT, peptide, and compounded options for menopause symptoms
- Prescribed and monitored by named board-certified physicians at Arora Health & Aesthetics, with dose adjustments included
- Verifiable LegitScript certification (seal ID 50917967)
- GLP-1 from $179/month with $0 membership fees, FSA/HSA eligibility, free shipping, and cancel-anytime
- Compounded semaglutide and tirzepatide, 100% online with a roughly 2-minute intake
Where it loses points
- Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Built for women navigating menopause — less tailored if that is not your situation
- A separate $50 physician consultation fee applies on top of the medication price
- The compounding pharmacy partner is not named, and the full list of served states is not published
Graded #192 · C
Strengths
- $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
- Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
- 45-state coverage
Where it loses points
- No LegitScript or PCAB accreditation
- No legal entity name or address disclosed
- No named pharmacy partners
- Not available in KS, LA, MS, NM, WV
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.